Compare STE & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STE | INCY |
|---|---|---|
| Founded | 1985 | 1991 |
| Country | United States | United States |
| Employees | 3700 | N/A |
| Industry | Industrial Specialties | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.9B | 17.0B |
| IPO Year | 2018 | 1994 |
| Metric | STE | INCY |
|---|---|---|
| Price | $215.78 | $96.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 21 |
| Target Price | ★ $275.20 | $103.52 |
| AVG Volume (30 Days) | 681.4K | ★ 1.3M |
| Earning Date | 05-11-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.19% | N/A |
| EPS Growth | 62.73 | ★ 4173.33 |
| EPS | ★ 5.69 | 1.47 |
| Revenue | ★ $5,459,515,000.00 | $3,394,635,000.00 |
| Revenue This Year | $9.88 | $10.44 |
| Revenue Next Year | $6.32 | $10.99 |
| P/E Ratio | ★ $38.45 | $66.42 |
| Revenue Growth | 6.24 | ★ 13.67 |
| 52 Week Low | $195.14 | $63.93 |
| 52 Week High | $269.44 | $112.29 |
| Indicator | STE | INCY |
|---|---|---|
| Relative Strength Index (RSI) | 50.90 | 48.40 |
| Support Level | $214.70 | $93.17 |
| Resistance Level | $227.10 | $103.11 |
| Average True Range (ATR) | 7.43 | 2.54 |
| MACD | 1.17 | -0.24 |
| Stochastic Oscillator | 88.04 | 26.49 |
Steris is an Ireland-domiciled medical technology company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Steris also sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its inversion to Ireland, the firm derives approximately 70% of its revenue from Healthcare Services, 19% from Applied Sterilization Technologies, or AST, and 11% from life sciences services after the divestment of its dental products business.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.